{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T01:18:15Z","timestamp":1772587095980,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ijgc.2025.101935","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T23:43:24Z","timestamp":1747871004000},"page":"101935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1073-8688","authenticated-orcid":false,"given":"Dana M.","family":"Chase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirwen M.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8605-5472","authenticated-orcid":false,"given":"Lucy","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-5633","authenticated-orcid":false,"given":"Oleksandr","family":"Zub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cara","family":"Mathews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Angioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Teneriello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Gropp-Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-7816","authenticated-orcid":false,"given":"Anna K.L.","family":"Reyners","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noelle G.","family":"Cloven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-808X","authenticated-orcid":false,"given":"Gemma","family":"Eminowicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beata","family":"Ma\u0107kowiak-Matejczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhavana","family":"Pothuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Samou\u00eblian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Boone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Bouberhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Braly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5472-4107","authenticated-orcid":false,"given":"Barbara","family":"Buttin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floor J.","family":"Backes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8855-9340","authenticated-orcid":false,"given":"Grace","family":"Antony","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie","family":"Garside","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Odette","family":"Allonby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolyn K.","family":"McCourt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mansoor Raza","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.101935_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101935_bib2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ijgc.2025.101935_bib3","series-title":"Cancer facts and figures","year":"2024"},{"issue":"4","key":"10.1016\/j.ijgc.2025.101935_bib4","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101935_bib5","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1200\/JCO.2015.61.6706","article-title":"American Society of Clinical Oncology statement: a conceptual framework to assess the value of cancer treatment options","volume":"33","author":"Schnipper","year":"2015","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101935_bib6","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1093\/annonc\/mdx310","article-title":"ESMO-Magnitude of Clinical Benefit Scale version 1.1","volume":"28","author":"Cherny","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2025.101935_bib7","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","article-title":"Informing the tolerability of cancer treatments using patient-reported outcome measures: summary of an FDA and Critical Path Institute Workshop","volume":"21","author":"Kluetz","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.ijgc.2025.101935_bib8","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1002\/pon.5054","article-title":"Quality of life versus length of life considerations in cancer patients: a systematic literature review","volume":"28","author":"Shrestha","year":"2019","journal-title":"Psychooncology"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101935_bib9","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1002\/cncr.23968","article-title":"Cancer patient preferences for quality and length of life","volume":"113","author":"Meropol","year":"2008","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101935_bib10","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1002\/cncr.30662","article-title":"Q-TWiST: what really matters to the cancer patient?","volume":"123","author":"Husson","year":"2017","journal-title":"Cancer"},{"issue":"23","key":"10.1016\/j.ijgc.2025.101935_bib11","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ijgc.2025.101935_bib12","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.annonc.2024.05.546","article-title":"Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6\/GOG-3031\/RUBY trial","volume":"35","author":"Powell","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.101935_bib13","unstructured":"JEMPERLI. Prescribing information. GSK. Accessed February 18, 2025. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Jemperli\/pdf\/JEMPERLI-PI-MG.PDF."},{"key":"10.1016\/j.ijgc.2025.101935_bib14","unstructured":"JEMPERLI. European Medicines Agency summary of product characteristics. GSK. Accessed February 18, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jemperli-epar-product-information_en.pdf."},{"issue":"1","key":"10.1016\/j.ijgc.2025.101935_bib15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0962280209105020","article-title":"Pseudo-observations in survival analysis","volume":"19","author":"Andersen","year":"2010","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.ijgc.2025.101935_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhealeco.2017.06.013","article-title":"Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis","volume":"55","author":"Hern\u00e1ndez-Alava","year":"2017","journal-title":"J Health Econ"},{"issue":"2","key":"10.1016\/j.ijgc.2025.101935_bib17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","article-title":"Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study","volume":"41","author":"Hern\u00e1ndez Alava","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.ijgc.2025.101935_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.101935_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2307\/2331554","article-title":"The probable error of a mean","volume":"6","year":"1908","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.ijgc.2025.101935_bib20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11136-005-1579-7","article-title":"Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data","volume":"15","author":"Revicki","year":"2006","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijgc.2025.101935_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241277656","article-title":"Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO\/GOG-3031\/RUBY)","volume":"16","author":"Auranen","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ijgc.2025.101935_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"10.1016\/j.ijgc.2025.101935_bib23","first-page":"A28","article-title":"639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG-3031\/RUBY trial","volume":"34","author":"Nov\u00e1k","year":"2024","journal-title":"Int J Gynecol Cancer"},{"issue":"36","key":"10.1016\/j.ijgc.2025.101935_bib24","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2, suppl 1","key":"10.1016\/j.ijgc.2025.101935_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijgc.2024.100243","article-title":"Patient-reported outcomes in patients with primary advanced or recurrent endometrial cancer treated with chemotherapy plus dostarlimab or placebo in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial over 3 years of follow-up","volume":"35","author":"Sharma","year":"2025","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 16","key":"10.1016\/j.ijgc.2025.101935_bib26","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1200\/JCO.2024.42.16_suppl.5607","article-title":"Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO\/GOG-3031\/RUBY trial","volume":"42","author":"Lokich","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijgc.2025.101935_bib27","doi-asserted-by":"crossref","unstructured":"Valabrega G, Powell MA, Hietanen S, et al. Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient\/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO\/GOG3031\/RUBY trial. Int J Gynecol Cancer. 2025;35(6):101852. https:\/\/doi.org\/10.1136\/ijgc-2024-005484.","DOI":"10.1136\/ijgc-2024-005484"},{"issue":"10","key":"10.1016\/j.ijgc.2025.101935_bib28","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1136\/ijgc-2022-003492","article-title":"Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient\/microsatellite instability-high endometrial cancer treated with dostarlimab","volume":"32","author":"Kristeleit","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"suppl 5","key":"10.1016\/j.ijgc.2025.101935_bib29","article-title":"Quality-adjusted survival in patients with advanced or recurrent endometrial carcinoma treated with atezolizumab in combination with carboplatin-paclitaxel versus carboplatin-paclitaxel in the AtTEnd\/ENGOT-EN7 trial","volume":"9","author":"Barretina Ginesta","year":"2024","journal-title":"ESMO Open"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25010552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T15:39:14Z","timestamp":1751643554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25010552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1048891X25010552"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101935","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.101935","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of European Society of Gynaecological Oncology and the International Gynecologic Cancer Society.","name":"copyright","label":"Copyright"}],"article-number":"101935"}}